Evolus, Inc. (NASDAQ:EOLS – Get Free Report) has been given an average rating of “Moderate Buy” by the six ratings firms that are currently covering the company, Marketbeat.com reports. Weiss Ratings upgraded Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. BTIG Research reaffirmed a “buy” rating and issued a $13.00 price target on shares of Evolus in a research report on Wednesday, June 17th. 10,539 shares of the company’s stock traded hands, compared to its average volume of 1,021,845. Evolus Company Profile(Get Free Report)Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics.